文章：

神奇青蛙及其应用领域：通过系统回顾临床前证据揭示隐丹参酮在抗击肺癌发生与发展中的潜在前景

Fantastic Frogs and Where to Use Them: Unveiling the Hidden Cinobufagin’s Promise in Combating Lung Cancer Development and Progression Through a Systematic Review of Preclinical Evidence

原文发布日期：7 November 2024

DOI: 10.3390/cancers16223758

类型: Article

开放获取: 是

英文摘要：

Cinobufagin (CB), a bufadienolide, has shown promising potential as an anticancer agent, particularly in combating lung cancer. This systematic review synthesizes preclinical evidence on CB’s effects against lung cancer, focusing on its mechanisms of action, efficacy, and potential clinical implications. We analyzed data from various preclinical studies involving both in vitro cell line models and in vivo animal models. The reviewed studies indicate that CB effectively reduces cell viability, induces apoptosis, and inhibits cell proliferation, migration, and invasion across multiple lung cancer cell lines and xenograft models. Specifically, CB was found to decrease cell viability and increase apoptosis in lung cancer cells by modulating key molecular pathways, including Bcl-2, Bax, cleaved caspases, caveolin-1, FLOT2, Akt, STAT3, and FOXO1. In vivo studies further demonstrated significant inhibition of tumor growth with minimal toxicity. However, limitations include reliance on in vitro models, which may not fully represent in vivo tumor dynamics, and a lack of long-term safety data. The studies also vary in their methodologies and cell line models, which may not accurately encompass all lung cancer subtypes or predict human responses. Despite these limitations, CB’s ability to target specific molecular pathways and its promising results in preclinical models suggest it could be a valuable addition to lung cancer treatment strategies. Our review suggests further clinical trials to validate its efficacy and safety in humans. Future research should explore combination therapies and optimize delivery methods to enhance clinical outcomes.

摘要翻译： 

华蟾毒配基(CB)作为一种蟾蜍二烯内酯，已显示出作为抗癌药物尤其是抗肺癌药物的良好潜力。本系统综述综合了关于CB抗肺癌作用的临床前证据，重点关注其作用机制、疗效及潜在的临床意义。我们分析了来自多种临床前研究的数据，包括体外细胞系模型和体内动物模型。综述研究表明，CB在多种肺癌细胞系和异种移植模型中能有效降低细胞活力、诱导细胞凋亡，并抑制细胞增殖、迁移和侵袭。具体而言，研究发现CB通过调控Bcl-2、Bax、cleaved caspases、caveolin-1、FLOT2、Akt、STAT3和FOXO1等关键分子通路，降低肺癌细胞活力并促进细胞凋亡。体内研究进一步证明CB能显著抑制肿瘤生长且毒性较低。然而，现有研究存在一定局限性，包括依赖体外模型（可能无法完全反映体内肿瘤动态）以及缺乏长期安全性数据。各研究在方法和细胞系模型上的差异，也可能导致其无法准确涵盖所有肺癌亚型或预测人体反应。尽管存在这些局限，CB靶向特定分子通路的能力及其在临床前模型中的良好效果，表明它可能成为肺癌治疗策略的重要补充。本综述建议开展进一步临床试验以验证其在人体中的有效性和安全性。未来研究应探索联合治疗方案并优化给药方式，以提升临床疗效。

原文链接：

Fantastic Frogs and Where to Use Them: Unveiling the Hidden Cinobufagin’s Promise in Combating Lung Cancer Development and Progression Through a Systematic Review of Preclinical Evidence